Key result
Review outlines anticoagulation management for cancer-associated thrombosis, specifically isolated distal DVT and incidental PE.
Why the study?
It remains questioned whether small or asymptomatic thromboses, such as isolated distal deep vein thromboses and subsegmental pulmonary emboli detected in cancer patients, require anticoagulation management similar to proximal or symptomatic thromboses.
Does anticoagulation improve outcomes in patients with cancer and isolated distal deep vein thromboses or subsegmental pulmonary emboli?
Does anticoagulation improve outcomes in patients with cancer and isolated distal deep vein thromboses or subsegmental pulmonary emboli?
This review provides clinical context and management strategies for cancer-associated thrombosis, particularly addressing the clinical dilemma of treating isolated distal DVT and subsegmental PE.
Answers are grounded in this paper and cite their sources.
Anticoagulation decisions for cancer-associated isolated distal DVT or incidental PE warrant individualized caution; leaves open the need for dedicated prospective trials.
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice. Venous thromboembolism occurs frequently in patients with cancer and is the second leading cause of death, after the cancer itself. There is a well-established consensus of the need for anticoagulation in patients with a proximal deep vein thrombosis or pulmonary embolism. But with improved imaging technology and widescale use of contrast imaging for cancer staging, many incidental pulmonary emboli are detected in patients with cancer. Furthermore, many isolated distal deep vein thromboses and subsegmental pulmonary emboli are identified. There have been questions if these small or asymptomatic thromboses require anticoagulation management similar to more proximal or symptomatic thromboses. In this Oncology Grand Rounds, we will review the existing evidence for these situations. We will also review management strategies for cancer-associated thrombosis, reflecting the evolving drugs and evidence over the past 20 years.
No takes yet. Share an insight, caveat, or question.
Gerald A. Soff (2024) conducted a review in Cancer-Associated Thrombosis. Anticoagulation was evaluated. This review outlines management strategies for cancer-associated thrombosis, specifically addressing the clinical dilemma of anticoagulating isolated distal deep vein thromboses and incidental pulmonary emboli.
Synapse has enriched 10 related papers. Consider them for comparative context: